{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T23:40:56Z","timestamp":1792885256015,"version":"4.5.0"},"reference-count":9,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can. J. Neurol. Sci."],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>ABSTRACT:<\/jats:title><jats:p>Prospectively acquired Canadian cerebrospinal fluid samples were used to assess the performance characteristics of three ante-mortem tests commonly used to support diagnoses of Creutzfeldt\u2013Jakob disease. The utility of the end-point quaking-induced conversion assay as a test for Creutzfeldt\u2013Jakob disease diagnoses was compared to that of immunoassays designed to detect increased amounts of the surrogate markers 14-3-3\u03b3 and hTau. The positive predictive values of the end-point quaking-induced conversion, 14-3-3\u03b3, and hTau tests conducted at the Prion Diseases Section of the Public Health Agency of Canada were 96%, 68%, and 66%, respectively.<\/jats:p>","DOI":"10.1017\/cjn.2020.139","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T03:19:14Z","timestamp":1594351154000},"page":"127-129","source":"Crossref","is-referenced-by-count":12,"title":["Prospective Study Demonstrates Utility of EP-QuIC in Creutzfeldt\u2013Jakob Disease Diagnoses"],"prefix":"10.1017","volume":"48","author":[{"given":"Sharon L. R.","family":"Simon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clark","family":"Phillipson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meika","family":"Richmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4316-7666","authenticated-orcid":false,"given":"Gerard H.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. David","family":"Knox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2020,7,10]]},"reference":[{"key":"S0317167120001390_ref6","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00542-16"},{"key":"S0317167120001390_ref5","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-7244-9_14"},{"key":"S0317167120001390_ref7","unstructured":"7. WHO and European Creutzfeldt-Jakob Disease Surveillance Network criteria, as referenced and posted on the website of the UK national CJD research and surveillance unit (NCJDRSU). Available at: https:\/\/www.cjd.ed.ac.uk\/sites\/default\/files\/criteria.pdf, accessed May 6, 2020."},{"key":"S0317167120001390_ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(97)00215-2"},{"key":"S0317167120001390_ref4","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.130720"},{"key":"S0317167120001390_ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199609263351303"},{"key":"S0317167120001390_ref9","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316853"},{"key":"S0317167120001390_ref8","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23589"},{"key":"S0317167120001390_ref1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-802395-2.00028-6"}],"container-title":["Canadian Journal of Neurological Sciences \/ Journal Canadien des Sciences Neurologiques"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0317167120001390","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T08:33:14Z","timestamp":1611045194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0317167120001390\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,10]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0317167120001390"],"URL":"https:\/\/doi.org\/10.1017\/cjn.2020.139","relation":{},"ISSN":["0317-1671","2057-0155"],"issn-type":[{"value":"0317-1671","type":"print"},{"value":"2057-0155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,10]]}}}